What should I avoid while taking Timolol 10mg / Bendroflumethiazide 2.5mg tablets?

Take with food. Food increases bioavailability. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Timolol 10mg / Bendroflumethiazide 2.5mg tablets?

Timolol 10mg / Bendroflumethiazide 2.5mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Timolol 10mg / Bendroflumethiazide 2.5mg tablets?

Timolol 10mg / Bendroflumethiazide 2.5mg tablets is the generic name. It is available under brand names including: Prestim tablets, Timolol 10mg / Bendroflumethiazide 2.5mg tablets, Timolol 10mg / Bendroflumethiazide 2.5mg tablets, Timolol 10mg / Bendroflumethiazide 2.5mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Antihypertensive

Unlicensed beta-blocker

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide.

Active ingredients:

Timolol + Bendroflumethiazide

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

C07BA06

WHO Anatomical Therapeutic Chemical code

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Unlicensed beta-blocker

Check interactions for Timolol + Bendroflumethiazide

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Timolol + Bendroflumethiazide

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

Search EudraVigilance database

Browse substances A–Z in the European adverse reaction database

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

4 branded products available

4 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Timolol + Bendroflumethiazide on the MHRA register

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Viatris UK Healthcare Ltd

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

A A H Pharmaceuticals Ltd

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Alliance Healthcare (Distribution) Ltd

Prestim tablets

Meda Pharmaceuticals Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Price

£53.62indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

Tablet

80mg

Same therapeutic group

Nadolol 40mg / Bendroflumethiazide 5mg tablets

Tablet

40mg

Same therapeutic group

Co-prenozide 160mg/0.25mg modified-release tablets

Tablet

160mg/0.25mg

Same therapeutic group

Propranolol 160mg modified-release / Bendroflumethiazide 5mg capsules

Capsule

160mg

Same therapeutic group

Propranolol 80mg / Bendroflumethiazide 2.5mg capsules

Capsule

80mg

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42383311000001105

dm+d ID

42383311000001105

VTM (Virtual Therapeutic Moiety)

774769000

VMP (Virtual Medicinal Product)

42383311000001105

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C07BA06

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Randomised trials: 2 · 1963–2023

Sort

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combination or in Merck.

Coleen M Clineschmidt, Robert D Williams, Ellen Snyder, et al.

Ophthalmology, 1998

Randomised trial

Cited by 85

Faculty of 1000 evaluation for Hypotensive Effect of Latanoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in NTG Patients: A Randomized, Multicenter, Crossover Clinical Trial.

Elizabeth Hodapp

F1000 - Post-publication peer review of the biomedical literature, 2013

Randomised trial

Sub-effective doses of a bendroflumethiazide-imipramine combination offer greater synergistic antidepressant effect compared to a bendroflumethiazide-fluoxetine combination: an isobolographic analysis

Health Sciences Investigations Journal, 2023

Bendroflumethiazide/Furosemide/Spironolactone

Reactions Weekly, 2023

timolol, n.

Oxford English Dictionary, 2023

Travoprost/timolol/brinzolamide/brinzolamide/timolol

Reactions Weekly, 2023

Comparison of the corneal effects of latanoprost, fixed combination latanoprost–timolol, and timolol A double-masked, randomized, one-year study

J Lass

Ophthalmology, 2001

Cited by 72

The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP

Suzan Guven Yilmaz, Cumali Degirmenci, Yunus Emre Karakoyun, et al.

International Ophthalmology, 2017

Cited by 13

Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE®) once daily versus timolol maleate ophthalmic solution twice daily

Arthur H. Shedden, Jean Laurence, Andrea Barrish, et al.

Documenta Ophthalmologica, 2001

Cited by 52

Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension

Katsuyoshi Suzuki, Naomi Otsuka, Hiroko Hizaki, et al.

Advances in Therapy, 2018

Cited by 11

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

28 found

Half-life

8.5 hours

Mechanism

As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the…

Food interactions

1 warning

Human targets

6 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Absorbed relatively rapidly after oral administration

Half-life

8.5 hours

8.5 hours

Protein binding

96%

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

Properties:

solid

Avg. mass: 421.42 Da

DrugBank indication

For the treatment of high blood pressure and management of edema related to heart failure.

Also known as(53)

±-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

Bendrofluazide

Bendroflumethiazid

Bendrofluméthiazide

Bendroflumethiazide

Bendroflumethiazidum

Bendroflumetiazida

Molecular properties(19)

Drug interactions(1710)

Known interactions with other medicines. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Bendroflumethiazide is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Bendroflumethiazide is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Bendroflumethiazide may increase the hypotensive activities of Risperidone.

Check this interaction

Ceritinib

Moderate

DB09063

Bendroflumethiazide may increase the bradycardic activities of Ceritinib.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide.

Check this interaction

Alfuzosin

Moderate

DB00346

Alfuzosin may increase the hypotensive activities of Bendroflumethiazide.

Check this interaction

Amifostine

Moderate

DB01143

Bendroflumethiazide may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Bendroflumethiazide.

Check this interaction

Forasartan

Moderate

DB01342

Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Forasartan.

Check this interaction

Tasosartan

Moderate

DB01349

Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan.

Check this interaction

Saralasin

Moderate

DB06763

Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin.

Check this interaction

Fimasartan

Moderate

DB09279

Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Obinutuzumab

Moderate

DB08935

Bendroflumethiazide may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Bendroflumethiazide.

Check this interaction

Rituximab

Moderate

DB00073

Bendroflumethiazide may increase the hypotensive activities of Rituximab.

Check this interaction

Phentermine

Moderate

DB00191

Phentermine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Eletriptan

Moderate

DB00216

Eletriptan may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Methysergide

Moderate

DB00247

Methysergide may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Cabergoline

Moderate

DB00248

Cabergoline may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Zolmitriptan

Moderate

DB00315

Zolmitriptan may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Dihydroergotamine

Moderate

DB00320

Dihydroergotamine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Protriptyline

Moderate

DB00344

Protriptyline may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Methylergometrine

Moderate

DB00353

Methylergometrine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Mirtazapine

Moderate

DB00370

Mirtazapine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Phenylephrine

Moderate

DB00388

Phenylephrine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Lisuride

Moderate

DB00589

Lisuride may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Metaraminol

Moderate

DB00610

Metaraminol may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Ergotamine

Moderate

DB00696

Ergotamine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Nicergoline

Moderate

DB00699

Nicergoline may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Methoxamine

Moderate

DB00723

Methoxamine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Trimipramine

Moderate

DB00726

Trimipramine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Trifluoperazine

Moderate

DB00831

Trifluoperazine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Pseudoephedrine

Moderate

DB00852

Pseudoephedrine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Benzphetamine

Moderate

DB00865

Benzphetamine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Diethylpropion

Moderate

DB00937

Diethylpropion may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Naratriptan

Moderate

DB00952

Naratriptan may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Frovatriptan

Moderate

DB00998

Frovatriptan may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Methoxyflurane

Moderate

DB01028

Methoxyflurane may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Ergoloid mesylate

Moderate

DB01049

Ergoloid mesylate may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Dutasteride

Moderate

DB01126

Dutasteride may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Pergolide

Moderate

DB01186

Pergolide may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Finasteride

Moderate

DB01216

Finasteride may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Ergometrine

Moderate

DB01253

Ergometrine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Lisdexamfetamine

Moderate

DB01255

Lisdexamfetamine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Mephentermine

Moderate

DB01365

Mephentermine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Showing 50 of 1710 interactions

Food & lifestyle interactions

Take With Food

Take with food. Food increases bioavailability.

How it works

Mechanism of action

As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

Pharmacodynamics

Bendroflumethiazide, a thiazide diuretic, removes excess water from the body by increasing how often you urinate (pass water) and also widens the blood vessels which helps to reduce blood pressure. It inhibits Na⁺/Cl^- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Absorbed relatively rapidly after oral administration

Half-life

8.5 hours

Protein binding

96%

Drug targets(6)

Proteins and enzymes this drug interacts with in the body

Solute carrier family 12 member 3

BE0000419

SLC12A3

inhibitor

Specific functionATP binding

Cellular location

Cell membrane

General function & pharmacology

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules .
PMID:18270262 PMID:21613606 PMID:22009145 PMID:36351028 PMID:36792826

Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity)

Calcium-activated potassium channel subunit alpha-1

BE0000553

KCNMA1

inducer

Specific functionactin binding

Cellular location

Cell membrane

General function & pharmacology

Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+) .
PMID:14523450 PMID:29330545 PMID:31152168

It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential.

Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map.

Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX). Possibly induces sleep when activated by melatonin and through melatonin receptor MTNR1A-dependent dissociation of G-beta and G-gamma subunits, leading to increased sensitivity to Ca(2+) and reduced synaptic transmission PMID:32958651

Solute carrier family 12 member 1

BE0000502

SLC12A1

blocker

Specific functionsodium

Cellular location

Apical cell membrane

General function & pharmacology

Renal sodium, potassium and chloride ion cotransporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation .
PMID:21321328
Electrically silent transporter system (By similarity)

Carbonic anhydrase 1

BE0000267

CA1

inhibitor

Specific functionarylesterase activity

Cellular location

Cytoplasm

General function & pharmacology

Catalyzes the reversible hydration of carbon dioxide .
PMID:10550681 PMID:16506782 PMID:16686544 PMID:16807956 PMID:17127057 PMID:17314045 PMID:17407288 PMID:18618712 PMID:19186056 PMID:19206230

Can hydrate cyanamide to urea PMID:10550681

Carbonic anhydrase 2

BE0000322

CA2

inhibitor

Specific functionarylesterase activity

Cellular location

Cytoplasm

General function & pharmacology

Catalyzes the reversible hydration of carbon dioxide .
PMID:11327835 PMID:11802772 PMID:11831900 PMID:12056894 PMID:12171926 PMID:1336460 PMID:14736236 PMID:15300855 PMID:15453828 PMID:15667203 PMID:15865431 PMID:16106378 PMID:16214338 PMID:16290146 PMID:16686544 PMID:16759856 PMID:16807956 PMID:17127057 PMID:17251017 PMID:17314045 PMID:17330962 PMID:17346964 PMID:17540563 PMID:17588751 PMID:17705204 PMID:18024029 PMID:18162396 PMID:18266323 PMID:18374572 PMID:18481843 PMID:18618712 PMID:18640037 PMID:18942852 PMID:1909891 PMID:1910042 PMID:19170619 PMID:19186056 PMID:19206230 PMID:19520834 PMID:19778001 PMID:7761440 PMID:7901850 PMID:8218160 PMID:8262987 PMID:8399159 PMID:8451242 PMID:8485129 PMID:8639494 PMID:9265618 PMID:9398308

Can also hydrate cyanamide to urea .
PMID:10550681 PMID:11015219
Stimulates the chloride-bicarbonate exchange activity of SLC26A6 .
PMID:15990874
Essential for bone resorption and osteoclast differentiation .
PMID:15300855
Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

TPMTThiopurine S-methyltransferase

inhibitor

Biological pathways(1)

Bendroflumethiazide Action Pathway

Involved compounds

Bendroflumethiazide,Cysteine,Potassium cation,Urea

ATC classification(4 codes)

ATC C03AB01

ATC C03EA13

ATC G01AE10

ATC C03AA01

Affected organisms(1)

Humans and other mammals

Experimental properties(5)

External resources(1)

Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 Mar 2026

Back to medicines

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Clinical essentials

Pharmacology

Deep science
8

Chemical identifiers

DrugBank citations

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Clinical essentials

Pharmacology

Deep science
8

Chemical identifiers

DrugBank citations

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Clinical essentials

Pharmacology

Deep science8

Chemical identifiers

DrugBank citations

Timolol 10mg / Bendroflumethiazide 2.5mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Clinical essentials

Pharmacology

Deep science8

Chemical identifiers

DrugBank citations

Deep science
8

Deep science
8